Sofinnova Investments, Inc. Mirati Therapeutics, Inc. Transaction History

Sofinnova Investments, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$132.01 - $190.29 $7.51 Million - $10.8 Million	-56,900 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$132.13 - $177.45 $2.86 Million - $3.84 Million	-21,638 Reduced 27.55%	56,900 $10.1 Million
Q2 2021 Aug 16, 2021	SELL	$144.0 - $179.73 $8.57 Million - $10.7 Million	-59,492 Reduced 43.1%	78,538 $12.7 Million
Q1 2021 May 14, 2021	BUY	$158.92 - $221.61 $21.9 Million - $30.6 Million	138,030 New	138,030 $23.6 Million
Q3 2020 Nov 13, 2020	SELL	$113.26 - $167.27 $914,234 - $1.35 Million	-8,072 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$72.01 - $120.39 $581,264 - $971,788	8,072 New	8,072 $922,000
Q1 2020 May 13, 2020	SELL	$69.78 - $116.21 $7.56 Million - $12.6 Million	-108,383 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$70.76 - $128.86 $5.49 Million - $10 Million	77,583 Added 251.89%	108,383 $14 Million
Q3 2019 Nov 14, 2019	BUY	$77.91 - $109.6 $2.4 Million - $3.38 Million	30,800 New	30,800 $2.4 Million
Q2 2018 Aug 14, 2018	SELL	$26.05 - $52.4 $226,322 - $455,251	-8,688 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$17.2 - $34.95 $149,433 - $303,645	8,688 New	8,688 $267,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Sofinnova Investments, Inc., based on Form 13F filings with the SEC.

Stay updated on Sofinnova Investments, Inc. with notifications on news.